Wednesday, 14 December 2016

Deal-Hungry Sanofi Shouldn't Overpay for Actelion

Pharma giant Sanofi risks paying too much for a rare-disease biotech.

from WSJ.com: Markets http://ift.tt/2hu8Oix
via https://ifttt.com/ IFTTT
Posted by at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)